The role of natriuretic peptide testing in guiding chronic heart failure management: Review of available data and recommendations for use  by Januzzi, James L.
AR
T
c
a
R
c
H
N
1
drchives of Cardiovascular Disease (2012) 105, 40—50
Available  online  at
www.sciencedirect.com
EVIEW
he  role  of  natriuretic  peptide  testing  in  guiding
hronic heart  failure  management:  Review  of
vailable data  and  recommendations  for  use
ôle  des  peptides  natriurétiques  pour  guider  le  traitement  de  l’insufﬁsance
ardiaque  chronique  :  revue  des  données  disponibles  et  recommandations
James L.  Januzzi  Jr. ∗
Division  of  Cardiology,  Massachusetts  General  Hospital,  MA  02114,  Yawkey  5984,  Boston,  USA
Received  14  October  2011;  accepted  15  October  2011
Available  online  16  January  2012
KEYWORDS
Natriuretic  peptides;
Heart  failure;
Outcomes
Summary  The  care  of  patients  with  heart  failure  can  be  challenging,  with  few  objective
tools  available  to  assist  in  therapy  decision-making.  Natriuretic  peptides  are  powerfully  prog-
nostic  biomarkers  in  patients  with  heart  failure  and  may  represent  an  objective  target  for
therapy.  Accordingly,  the  use  of  biomarker-guided  care  with  either  B-type  natriuretic  pep-
tide  (BNP)  or  amino-terminal  pro-B-type  natriuretic  peptide  (NT-proBNP)  has  been  recently
explored.  Over  the  past  few  years,  a  number  of  studies  with  heterogeneous  inclusion  criteria,
methods  and  results  have  been  performed.  We  have  reviewed  the  available  literature,  sum-
marizing  the  results  of  biomarker-guided  heart  failure  trials  and  deriving  recommendations  for
optimal  application  of  biomarker-guided  heart  failure  care  based  on  the  experience  gained.
In  general,  positive  studies  had  low  BNP  or  NT-proBNP  target  concentrations  (∼100  pg/mL  and
∼1000  pg/mL,  respectively)  and  achieved  lower  natriuretic  peptide  concentrations  compared
with  standard  care.  Patients  in  the  biomarker-guided  arms  of  the  studies  typically  received
more  aggressive  heart  failure  care  and  had  no  excess  adverse  outcomes.  In  the  recent  ProBNP
Outpatient  Tailored  Chronic  Heart  Failure  Therapy  (PROTECT)  study,  patients  treated  with
biomarker-guided  care  also  had  improved  quality  of  life  and  signiﬁcantly  better  reverse  remo-
deling  on  echocardiography  compared  with  patients  who  received  standard  care.  In  conclusion,
Abbreviations: ACE, Angiotensin-converting enzyme; ARBs, Angiotensin receptor blockers; BNP, B-type natriuretic peptide;
F, Heart failure; HFpEF, Heart failure with preserved ejection fraction; LVSD, Left ventricular systolic dysfunction;
T-proBNP,  Amino-terminal pro-B-type natriuretic peptide.
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heart  failure  therapy  guided  by  a  goal  to  reduce  natriuretic  peptide  concentrations  below
prognostically-meaningful  levels  results  in  more  aggressive  heart  failure  care,  is  well  tolerated
and  is  associated  with  superior  outcomes.
©  2011  Elsevier  Masson  SAS.  
MOTS  CLÉS
Peptides
natriurétiques  ;
Insufﬁsance
cardiaque ;
Évènements  lors  du
suivi
Résumé  La  prise  en  charge  des  patients  en  insufﬁsance  cardiaque  peut  être  difﬁcile  avec
la  faible  disponibilité  des  moyens  pour  guider  le  traitement  et  la  décision  thérapeutique.  Les
peptides  natriurétiques  sont  des  biomarqueurs  ayant  un  impact  sur  l’évaluation  du  pronostic
des  patients  en  insufﬁsance  cardiaque  et  pourraient  être  utiles  pour  guider  le  traitement.  Ainsi,
cette  hypothèse  a  été  testée,  en  évaluant  les  résultats  concernant  le  peptide  natriurétique  de
type  B  (BNP)  ou  le  proBNP  (NT-proBNP).  Dans  les  années  écoulées,  de  nombreuses  études  avec
cependant  des  critères  d’inclusion,  des  méthodes  et  des  résultats  hétérogènes  ont  été  réalisées.
Nous  avons  revu  les  données  disponibles  de  la  littérature  et  résumé  les  résultats  concernant  la
prise  en  charge  de  l’insufﬁsance  cardiaque  guidée  par  la  prise  en  compte  du  taux  de  peptide
natriurétique,  et  ainsi  proposer  des  recommandations  aﬁn  de  prendre  en  considération  ces  don-
nées  biologiques  pour  orienter  de  fac¸on  optimale  le  traitement.  De  fac¸on  globale,  les  études
positives  avaient  des  objectifs  de  concentration  de  BNP  ou  de  NT-proBNP  bas  (respectivement
100 pg/mL  et  1000  pg/mL)  et  ont  atteint  des  concentrations  de  peptide  natriurétique  plus  bas,
comparativement  à  la  prise  en  charge  standard.  Les  patients  inclus  dans  le  bras  guidé  par  le
taux  de  biomarqueurs,  dans  ces  études,  étaient  traités  de  fac¸on  plus  agressive  et  n’avaient  pas
d’augmentation  du  risque  de  survenue  d’évènements  cardiovasculaires.  Dans  l’étude  la  plus
récente,  ProBNP  Outpatient  Tailored  Chronic  Heart  Failure  Therapy  (PROTECT),  les  patients
en  insufﬁsance  cardiaque  traités  en  prenant  en  considération  le  taux  de  peptide  natriurétique
avaient  également  une  amélioration  de  la  qualité  de  la  vie,  ainsi  qu’une  correction  signiﬁ-
cative  du  remodelage  ventriculaire  gauche  évaluée  par  échocardiographie  comparativement
aux patients  pris  en  charge  dans  une  stratégie  thérapeutique  conventionnelle,  ne  prenant  pas
en  considération  les  taux  de  biomarqueurs.  En  conclusion,  le  traitement  de  l’insufﬁsance  car-
diaque  orienté  et  guidé  par  la  prise  en  compte  des  concentrations  de  peptides  natriurétiques,
en visant  un  objectif  de  la  concentration  la  plus  basse  conduit  à  une  prise  en  charge  optimale
car  plus  agressive  de  l’insufﬁsance  cardiaque,  et  est  bien  tolérée  et  est  associée  à  un  moindre
risque  de  complication  cardiovasculaire  lors  du  suivi.
©  2011  Elsevier  Masson  SAS.  
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invasive  haemodynamic  and  impedance  monitors  require
validation and  lack  substantial  data  regarding  their  use-
fulness in  guiding  therapy  [2—4].  One  intriguing  option  is
Table  1  Examples  of  available  or  proposed  options
for  advanced  monitoring  of  patients  with  chronic  heart
failure.
Non-invasive  Invasive
Echocardiography  Transthoracic
impedance
monitoring
Bio-impedance  vector
monitoring
Left atrial  pressure
monitoring
Auditory  S3  monitoring  Pulmonary  artery
pressure monitoring
Open access under CC BY-NC-ND license.
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In  modern  practice,  there  are  numerous  challenges  to  be
faced when  trying  to  deliver  optimal  care  to  patients  with
chronic HF.  Among  these  are  the  fact  that  it  is  a  major
challenge to  achieve  an  optimal  medical  programme  that
minimizes HF  symptoms  and  potential  side  effects  while
achieving the  pre-speciﬁed  goal  doses  of  these  therapies.
Further, it  is  a  challenge  to  easily  identify  when  those  goal
doses are  achieved.  Frequent  ofﬁce  visits  with  constant
evaluation and  management  are  often  needed  to  optimize
care; this,  more  often  than  not,  requires  great  skill  in  reco-
gnizing opportunities  to  titrate  therapies  and  the  acumen  to
implement such  changes.
Despite  clearly  deﬁned  targets  for  HF  care  worldwide,
there is  well-documented  inconsistency  in  adherence  to  HF
practice guidelines  [1],  with  eligible  patients  being  under-
treated and  opportunities  to  optimize  care  frequently  being
missed.  This  has  led  to  a  considerable  focus  on  methods  to
identify those  patients  in  need  of  therapy  titration  and  to
stratify risk  in  an  objective  manner,  in  order  to  better  deliver
care to  those  patients  at  highest  risk  of  an  adverse  outcome.
Very few  tools  for  this  exist,  beyond  clinical  judgment,  and
the everyday  clinician  has  very  few  easily-obtainable,  inex-
pensive and  widely-available  resources  to  draw  on  to  supportheir  judgment  regarding  the  management  of  a  patient  with
hronic HF.  Several  emerging  options  are  listed  in  Table  1.
Haemodynamic  monitoring  devices  offer  promise  but
lmost universally  require  invasive  placement,  while  non-Non-invasive  cardiac  output
monitoring
Biomarker-guided monitoring
4 J.L.  Januzzi  Jr.
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Table  2  Cardiac  abnormalities  associated  with  eleva-
tion  of  B-type  natriuretic  peptide  (BNP)  or  amino-
terminal  pro-B-type  natriuretic  peptide  (NT-proBNP).
Characteristic
Myocardial  processes
Systolic dysfunction
Diastolic  dysfunction
Fibrosis/scar
Hypertrophy
Inﬁltrative  diseases
Valvular abnormalities
Mitral stenosis,  regurgitation
Aortic stenosis,  regurgitation
Tricuspid regurgitation
Pulmonic stenosis
Cardiac chamber  size
Ventricular enlargement
Atrial enlargement
Filling  pressures
Atrial,  ventricular
Pulmonary
Ischaemic  heart  disease
Coronary artery  ischaemia
Heart rhythm  abnormalities
Atrial ﬁbrillation,  ﬂutter
Pericardial diseases
Constriction,  tamponade
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he  use  of  biomarkers  to  assist  in  therapeutic  decision-
aking, which  is  attractive,  given  their  wide  availability
nd easy  measurement,  and  the  non-invasive  nature  of  the
pproach. Indeed,  the  natriuretic  peptides  —– BNP  and  its
mino-terminal propeptide  equivalent  (NT-proBNP)  —– have
een shown  to  provide  easily-obtainable  and  meaningful
rognostic information  in  chronic  HF,  which  is  linked  directly
o the  biology  of  the  diagnosis  and  is  additive  to  other
bjective means  of  assessing  risk.  Importantly,  as  will  be
iscussed, both  BNP  and  NT-proBNP  appear  not  only  to  be
ble to  identify  those  at  higher  risk  of  adverse  outcome  but
lso  to  show  interaction  with  HF  therapies,  such  that  their
erial measurement  may  also  provide  information  about  the
uccess or  failure  of  therapy  changes,  thus  allowing  BNP  or
T-proBNP to  act  as  targets  for  HF  care,  in  a  similar  manner
o blood  pressure  or  heart  rate.
In  order  to  better  understand  the  potential  role  of  BNP  or
T-proBNP in  guiding  HF  management,  a  brief  summary  of
he important  topics  relating  to  their  release,  their  prog-
ostic value  and  methods  for  interpreting  their  values  is
orthwhile. This  will  be  followed  by  a review  of  studies
xamining ‘‘biomarker-guided’’  therapy,  an  interpretation
f their  results  and  recommendations  for  application  of  BNP
r NT-proBNP  for  HF  care.
nterpretation of natriuretic peptide
oncentrations  in ambulatory heart failure
HF)
riggers for B-type natriuretic peptide (BNP)
r  amino-terminal pro-B-type natriuretic
eptide  (NT-proBNP) release
hile  the  topic  of  natriuretic  peptide  release  in  patients
ith chronic  HF  is  extensive  and  exceeds  the  scope  of  this
ocument, certain  concepts  are  worthwhile  discussing  in
etail.
Physiologically, it  is  reasonable  to  consider  the  concen-
ration of  either  BNP  or  NT-proBNP  as  being  the  sum  of  two
eparate components:  ﬂuid  and  function.
It  is  well  established  that  myocardial  stretch  conse-
uent to  volume  status  is  an  important  trigger  for  the
elease of  natriuretic  peptides  [5].  When  interpreting  results
or either  BNP  or  NT-proBNP,  clinicians  should  remember
hat a  signiﬁcant  percentage  of  their  release  is  triggered
y ﬁlling  pressures,  particularly  when  there  are  very  high
oncentrations of  either  peptide  (e.g.  BNP  >  500  pg/mL  or
T-proBNP >  5000  pg/mL).
Importantly,  however,  it  is  well  established  that  ﬁlling
ressures are  only  one  trigger  for  BNP  or  NT-proBNP  secre-
ion [6—8].  Of  the  wide  variety  of  structural  and  functional
ardiac abnormalities  leading  to  the  release  of  both  natri-
retic peptides  (detailed  in  Table  2),  it  is  fair  to  assert
hat the  prognostic  importance  of  each  is  known  and  that
otential therapeutic  interventions  exist  for  their  treat-
ent. Such  abnormalities  of  cardiac  structure  and  functionnclude left  ventricular  systolic  and  diastolic  dysfunction,
ulmonary artery  hypertension,  abnormal  right  ventricu-
ar size  and  function,  valvular  heart  disease  and  heart
hythm abnormalities  that  are  prevalent  in  patients  with
n
b
i
cCongenital abnormalities
Shunts, stenotic  lesions
ompensated  HF.  Therapeutic  interventions  to  address  each
re considered  below.
atriuretic peptides and prognosis in
mbulatory  heart failure (HF)
his  topic  has  been  recently  reviewed  in  detail  [9].  Both  BNP
nd NT-proBNP  represent  the  biomarker  ‘‘gold  standard’’
or prognostication  in  chronic  HF,  providing  independent
nformation regarding  risk  of  progression  of  HF,  ventricular
emodeling, hospitalization  for  HF,  need  for  transplantation
r death.  Concentrations  of  both  peptides  also  predict  the
isk of  arrhythmias  [10],  underscoring  their  value  to  prog-
osticate across  a  wide  range  of  adverse  outcomes  in  HF,
rom pump  complications  to  heart  rhythm  abnormalities.
While  a  single  measurement  of  BNP  or  NT-proBNP  pro-
ides useful  prognostic  data  for  such  adverse  outcomes,  it
s well  established  that  serial  measurement  provides  incre-
entally unique  information  [11—13].  Indeed,  compared
ith a  single  point  measurement,  the  addition  of  subsequent
nalysis of  BNP  or  NT-proBNP  allows  for  the  identiﬁcation
f changes  in  risk  over  time:  some  patients  have  a  falling
atriuretic peptide,  which  predicts  a  lower  risk  than  a
aseline value  might  suggest,  while  others  develop  a  ris-
ng pattern,  which  predicts  a  higher  likelihood  of  impending
omplications (Fig.  1).
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EFigure 1. Trends in natriuretic peptide concentrations add conside
amino-terminal pro-B-type natriuretic peptide.
Reproduced with permission from [13].
The  link  between  these  secular  trends  in  natriuretic
peptide concentrations  and  outcome  is  quite  important,
as it  implies  a  potential  value  of  BNP  or  NT-proBNP  for
‘‘monitoring’’ patients  at  each  ofﬁce  visit.  Indeed,  recent
guidelines stress  the  importance  of  serial  measurement  of
BNP or  NT-proBNP  for  this  indication  [14].  Logically,  one
recognizes the  importance  of  a  stable  natriuretic  peptide
concentration for  identifying  those  patients  who  are  less
likely to  have  progressive  HF,  while  in  those  with  a  high  or
changing concentration,  such  complications  are  more  likely
and more  careful  monitoring  would  be  recommended.
The  prognostic  thresholds  of  BNP  or  NT-proBNP  for
adverse outcomes  of  all  types  have  been  identiﬁed  [13,15]
and tend  to  be  at  the  lower  end  of  the  scale  of  what  is
expected relative  to  concentrations  seen  in  patients  with
acutely decompensated  HF.  For  BNP,  as  indicated  by  Mas-
son et  al.  [13],  it  would  appear  that  a  concentration  of
∼125 pg/mL  represents  the  inﬂection  point  for  risk,  while
repeated studies  have  more  solidly  established  a  concen-
tration of  1000  pg/mL  for  NT-proBNP.  Above  these  risk
thresholds, one  may  see  a  higher  risk  of  adverse  outcome,
while below  these  concentrations,  the  risk  tends  to  be  con-
siderably lower.
When  a  patient  is  truly  optimally  managed,  their  BNP  or
NT-proBNP concentration  may  be  considered  as  the  ‘‘dry’’
value. This  ‘‘dry’’  natriuretic  peptide  value  —– ostensibly  the
best result  a  patient  can  reach  —– may  then  be  used  to  assess
risk of  mortality  and  morbidity,  if  still  elevated  above  prog-
nostic thresholds,  as  will  be  discussed  next.
Interpreting B-type natriuretic peptide (BNP)
or  amino-terminal pro-B-type natriuretic
peptide  (NT-proBNP) concentrations in the
ofﬁce:  understanding changes and timing of
measurement
When  measuring  biomarkers,  it  is  common  to  see  a  rise
and/or fall  in  multiple  measures  of  physiological  function;
n
T
t to a single value for prognostication. HF: heart failure; NT-proBNP;
hen  in  the  absence  of  an  obvious  pathological  process,
his change  in  the  biomarker  is  known  as  biological  variabil-
ty. In  the  case  of  natriuretic  peptides,  biological  variability
s likely  to  be  related  to  subtle  changes  in  BNP  synthesis,
s well  as  to  dynamic  changes  in  cardiac  ﬁlling  pressures,
ulmonary pressure,  haemodynamics  and  changes  in  the
learance of  BNP  or  NT-proBNP.
While  biological  variability  is  considerably  higher  at  low
oncentrations of  BNP  and  NT-proBNP,  at  the  ranges  seen
n HF,  a  biological  variability  of  25%  for  NT-proBNP  and
0% for  BNP  is  more  to  be  expected  [16—18].  NT-proBNP
as a  longer  half-life,  which  may  be  responsible  for  lower
iological variability  than  BNP.  Thus,  a  rise  or  fall  of  25%
NT-proBNP) to  40%  (BNP)  implies  a  signiﬁcant  change  in
hysiology. This  point  is  particularly  important  to  know  when
aking decisions  about  changing  drug  therapy  based  on
NP or  NT-proBNP  concentrations.  Given  that  BNP  (with  its
horter half-life)  is  more  likely  to  be  labile  compared  with
T-proBNP (with  its  longer  half-life),  differences  in  moni-
oring (and  treatment  approaches)  using  the  two  peptides
re likely  to  exist,  with  greater  day-to-day  excursions  with
he former  peptide  and  a  smoother  integration  of  daily
hysiology with  the  latter.  How  this  relates  to  decisions
bout timing  and  method  of  intervention  with  BNP  versus
T-proBNP remains  somewhat  less  clear.
Another  important  topic  relevant  to  serial  testing  is  the
mount of  time  it  takes  after  a  physiological  change  for  BNP
r NT-proBNP  to  achieve  a  new  ‘‘steady  state’’.  While  bio-
ogical data  are  largely  lacking  in  this  regard,  on  a clinical
evel it  has  been  suggested  that  the  largest  prognostic  value
elative to  changes  in  NT-proBNP  concentration  is  observed
 weeks  after  a  therapy  change  [19].
ffect of heart failure (HF) therapies on
atriuretic  peptide concentrations
herapies  for  HF  directly  affect  the  processes  that  con-
ribute the  rise  of  BNP  or  NT-proBNP  and  are  likely  to  affect
44  
Table  3  Therapies  for  heart  failure  that  may  lower  B-
type  natriuretic  peptide  (BNP)  or  amino-terminal  pro-B-
type  natriuretic  peptide  (NT-proBNP)  concentrations.
Therapy  Effect  on  BNP/NT-proBNP
Diuresis  (loop  or  thiazide) ↓
ACE-I ↓
ARB  ↓
Beta-blockers  Some  transiently  ↑,  most  ↓
Aldosterone  antagonists  ↓
CRT  ↓
Exercise  ↓
Rate  control  of  AF ↓
BNP infusions N-BNP  ↓,  BNP  ↑  then  ↓
ACE-I: angiotensin-converting enzyme inhibitor; AF: atrial ﬁb-
rillation;  ARB: angiotensin receptor blocker; BNP: B-type
natriuretic peptide; CRT: cardiac resynchronization therapy;
NT-proBNP: amino-terminal pro-B-type natriuretic peptide.
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The  concept  of  utilizing  a  natriuretic  peptide  as  a  tar-he  biological  variability  of  natriuretic  peptides.  Thus,  it
s well  established  that  many  HF  therapies  lower  the  con-
entrations of  BNP  and  NT-proBNP  (Table  3).  These  include,
f course,  loop  diuretics,  but  also  ACE  inhibitors,  ARBs,
eta-blockers, aldosterone  antagonists,  exercise  therapy
nd cardiac  resynchronization  therapy  [5,20—37].
It  is  easy  to  understand  how  loop  diuretics  decrease  the
oncentrations of  BNP  and  NT-proBNP  through  their  effect
n cardiac  ﬁlling  pressures;  when  diuretics  are  withheld,
nequivocal increases  in  BNP  and  NT-proBNP  concentrations
g
a
d
Table  4  Summary  of  biomarker-guided  therapy  studies.
Age  HFpEF  Target  NP  concent
Negative  studies
STARBRITE  [46]  60  No  BNP  at  hospital
discharge  ∼450  pg/
TIME-CHF  [45]  77  No  NT-proBNP  less  tha
400 pg/mL  for  age
than  75  years  and
800 pg/mL  for  age
greater  or  equal  to
years
BATTLESCARRED  [43]  76  Yes  NT-proBNP  1270  pg
PRIMA  [42]  72  Yes  Individual  NT-proB
hospital discharge
SIGNAL-HF  [44]  78  No  NT-proBNP  50%  bel
trial entry
Positive  studies
Troughton  et  al.  [38]  70  No  NT-proBNP  1735  pg
STARS-BNP  [41]  65  No  BNP  100  pg/mL  
Berger  et  al.  [39]  71  No  NT-proBNP  2200  pg
PROTECT  [40,49]  63  No  NT-proBNP  1000  pg
BNP: B-type natriuretic peptide; HFpEF: heart failure with prese
amino-terminal  pro-B-type natriuretic peptide.J.L.  Januzzi  Jr.
ay  be  seen  [5].  On  the  other  hand,  non-loop  diuretics
uch as  spironolactone  or  eplerenone  (which  have  relatively
odest diuretic  effects)  also  have  a  substantial  effect  on
atriuretic peptide  concentrations.
On  the  other  hand,  neurohormonal  agents,  such  as  ACE
nhibitors and  ARBs,  cause  peptide  concentrations  to  fall
ue to  their  favourable  effects  on  ﬁlling  pressures  and  car-
iac haemodynamics  as  well  as  their  effects  on  ventricular
emodeling, while  non-vasodilating  beta-blockers  may  ini-
ially increase  natriuretic  peptide  concentrations,  which
ypically does  not  reﬂect  clinical  decompensation.  However,
n chronic  optimal  beta-blocker  therapy,  the  concentrations
f natriuretic  peptides  fall,  reﬂecting  the  remodeling  of
he left  ventricle.  Importantly,  an  unequivocal  interaction
etween natriuretic  peptides  and  response  to  beta-blocker
herapy has  been  found  in  the  ANZ  Heart  Failure  and  COPER-
ICUS trials  of  carvedilol  in  advanced  HF;  subjects  with
he highest  NT-proBNP  concentrations  appeared  to  gain  the
reatest beneﬁt  from  treatment  with  carvedilol.
In  addition  to  drug  therapy,  BNP  or  NT-proBNP  can  also  be
owered by  exercise  therapy  [25,33]  and  cardiac  resynchro-
ization therapy  [29],  both  important  adjuncts  to  the  care
f the  HF  patient.
atriuretic peptides for guiding heart
ailure  (HF) managementet for  therapy  was  ﬁrst  examined  more  than  10  years
go by  Troughton  et  al.  [38]  in  the  Christchurch  Cardioen-
ocrine Group.  In  their  seminal  study,  the  investigators
ration  Active  arm  with  lower
NP concentration  at
end of  trial?
Active  arm
treatment  different
from control  arm?
mL
No  Yes
n
 less
 75
No Yes
/mL  No  Yes
NP  at No No
ow No No
/mL  Yes  Yes
Unknown  Yes
/mL  Yes  Yes
/mL  Yes  Yes
rved ejection fraction; NP: natriuretic peptide; NT-proBNP:
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Reproduced with permission from [47].
demonstrated  that,  compared  with  HF  care  ‘‘guided’’  by
a congestion  score,  therapy  with  the  goal  of  suppress-
ing NT-proBNP  concentration  was  associated  with  superior
event-free survival.  Since  then,  several  other  trials  have
explored the  concept,  some  with  beneﬁt  from  guided  the-
rapy [39—41]  and  others  without  [42—46]  (Table  4).  Before
reviewing the  experience  gained  from  these  studies,  it  is
worthwhile emphasizing  that  whether  positive  or  negative,
pooled analyses  of  all  the  studies  in  this  area  (positive  and
negative) indicate  a  20  to  25%  adjusted  reduction  in  morta-
lity associated  with  biomarker-guided  care  on  top  of  stan-
dard management  (Fig.  2)  [47,48].
In  addition  to  the  fact  that  most  BNP-  or  NT-proBNP-
guided HF  studies  were  small  and  heterogeneous  in  size
compared with  each  other,  guided  therapy  studies  have
had variable  inclusion  criteria,  different  types  of  clini-
cians delivering  the  care  and  a  wide  range  of  goal
natriuretic peptide  concentrations,  and  the  interventions
to achieve  the  goal  concentrations  have  been  variably
applied and  variably  successful.  From  this  experience,  how-
ever,  more  and  more  clarity  is  being  gained  about  how
biomarker-guided care  may  be  of  greatest  value.  Indeed,
in retrospect,  it  is  possible  to  understand  why  some  trials
failed and  others  did  not.  With  such  an  understanding,
it may  be  possible  to  identify  where  the  approach  may
be best  applied  [49],  based  on  the  experience  gained,
in order  to  be  successful  with  BNP-  or  NT-proBNP-guided
care.
A low target natriuretic peptide concentration
is  necessary
Most  of  the  negative  trials  typically  chose  BNP  or  NT-
proBNP target  concentrations  that  were  too  high  to  improve
p
A
Bl results, suggesting a signiﬁcant reduction in risk of mortality.
utcomes  in  patients  managed  with  guided  therapy.  For
xample, in  STARBRITE  [46],  the  goal  BNP  concentration  was
lose to  450  pg/mL,  with  a  nominal  change  by  the  end  of  the
tudy (to  413  pg/mL),  which  was  no  different  from  biolo-
ical variability  for  the  peptide.  In  contrast,  in  the  positive
TARS-BNP trial,  the  goal  BNP  concentration  was  100  pg/mL
41].
In addition  to  having  inappropriately  high  target
atriuretic peptide  concentrations,  many  negative  trials,
ncluding STARBRITE,  achieved  no  natriuretic  peptide  sepa-
ation between  the  guided  therapy  and  standard  care  arms,
eaving the  strategy  untested.  To  be  successful,  achieve-
ent of  a  proper  target  concentration  is  necessary  (as
tated, for  BNP,  the  optimal  target  is  ∼125  pg/mL,  while
or NT-proBNP  it  is  ∼1000  pg/mL).  Notably,  studies  that
chieved improved  outcome  associated  with  guided  therapy,
uch as  the  STARS-BNP  or  ProBNP  Outpatient  Tailored  Chronic
eart Failure  Therapy  (PROTECT)  trials  [40,50],  had  a  low
arget natriuretic  peptide  concentration  (BNP,  100  pg/mL;
T-proBNP, 1000  pg/mL).
Interestingly, one  reason  for  negative  trials  in  this  area
as that  the  control  arm  received  high-quality  care  with
arallel suppression  of  the  BNP  or  NT-proBNP,  frequently
omparable to  the  unblinded  arm  [43].  Thus,  a  low  post-
reatment natriuretic  peptide  concentration  is  desirable,
hether as  a consequence  of  guided  therapy  or  simply  excel-
ent care.
espect the prognostic value of B-type
atriuretic  peptide (BNP) and amino-terminal
ro-B-type  natriuretic peptide (NT-proBNP)
 common  scenario  is  that  a  patient  may  have  an  elevated
NP or  NT-proBNP  concentration,  but  his/her  clinician  feels
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the  patient  is  stable  and  does  not  adjust  his/her  therapy.
Experience has  taught,  again  and  again,  that  no  matter  how
stable a  patient  with  HF  appears,  when  BNP  or  NT-proBNP
concentrations are  elevated  above  their  prognostic  thresh-
old, a  measurable  and  imminent  risk  is  present.  Ignoring  such
a powerful  objective  signal  of  risk  increases  the  likelihood
for a  missed  opportunity  to  improve  outcome.  Tellingly,  in
most of  the  negative  trials,  there  was  no  difference  in  ofﬁce
visits between  guided  versus  control  arms  [42,44],  whereas
a trade-off  of  increased  outpatient  visits  was  seen  in  the
successful studies.
It may take time and effort to lower B-type
natriuretic  peptide (BNP) and amino-terminal
pro-B-type  natriuretic peptide (NT-proBNP)
concentrations
While  the  low  target  BNP  or  NT-proBNP  concentrations  may
seem  unreachable  in  many  patients,  the  successful  trials  of
guided therapy  would  argue  otherwise  —– the  lesson  learned
is that  it  takes  gradual  drug  titration  and  more  ofﬁce  visits
to achieve  these  goals.  In  the  PROTECT  study,  one  of  the
most thoroughly  executed  studies  of  NT-proBNP-guided  care
to date,  signiﬁcant  lowering  of  NT-proBNP  was  achieved  in
the biomarker-guided  arm  but  it  required  extra  ofﬁce  visits
compared with  standard  HF  management.
In  practice,  it  is  common  to  ﬁnd  patients  in  whom  con-
centrations of  BNP  or  NT-proBNP  are  lowered,  but  do  not
achieve the  goal  value,  no  matter  how  hard  a  clinician
adjusts the  therapy.  Aggregate  experience  would  suggest
that any  lowering  is  better  than  no  lowering  at  all;  in  one
negative trial,  those  patients  in  the  trial  who  actually  had  a
robust reduction  in  NT-proBNP  concentration  had  improve-
ment in  outcome,  despite  the  negative  overall  trial  results
[42]. Lending  further  support  to  this,  in  the  PROTECT  study,
a clear  gradient  of  risk  was  present  relative  to  achieved
NT-proBNP concentrations:  those  patients  achieving  the  tar-
get of  1000  pg/mL  had  considerably  lower  risk  than  those  at
intermediate or  higher  values  (Fig.  3).  While  some  patients
Figure 3. Risk of adverse outcome as a function of achieved
amino-terminal pro-B-type natriuretic peptide (NT-proBNP) concen-
tration  in the ProBNP Outpatient Tailored Chronic Heart Failure
Therapy  (PROTECT) study. A rising risk was observed above the
target  concentration of amino-terminal pro-B-type natriuretic pep-
tide  ≤ 1000 pg/mL.
Reproduced with permission from [40].
Figure 4. The amount of time spent below the goal amino-
terminal pro-B-type natriuretic peptide (NT-proBNP) concentration
in  the ProBNP Outpatient Tailored Chronic Heart Failure Therapy
(PROTECT) study was inversely related to risk of adverse cardio-
vascular  events. Those patients who spent the whole trial with
a  concentration below 1000 pg/mL had the best outcomes, while
those  who met the target concentration some of the time had inter-
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iediate  outcomes and those who constantly had a concentration
bove 1000 pg/mL had the worst outcomes.
chieved  the  target  concentration  set  in  PROTECT  and  were
aintained  below  it,  others  only  achieved  it  intermittently
nd some  did  not  achieve  it  at  all;  those  constantly  below
n NT-proBNP  concentration  of  1000  pg/mL  had  the  best
utcomes, while  those  who  achieved  this  intermittently
ad intermediate  outcomes  and  those  with  concentrations
onstantly above  it  had  the  worst  outcomes  (Fig.  4).  This
oncept of  ‘‘therapeutic  time  in  response’’  is  very  similar
o that  seen  with  respect  to  beneﬁts  predicted  by  interna-
ional normalized  ratio  testing  during  vitamin  K  antagonist
herapy [51],  where  more  time  ‘‘in  range’’  is  associated  with
reater beneﬁt.
In summary,  ensuring  that  patients  get  as  close  to  the
arget natriuretic  peptide  concentration  as  possible  and
aintaining them  at  this  concentration  is  crucially  impor-
ant; the  goal  is  attainable  but  it  takes  time  and  effort.
hen using biomarker-guided therapy,
ddition  or up-titration of therapies should be
ased  on a treatment approach that reduces
orbidity  and mortality and be done with
ood  clinical judgment
hen  titrating  therapies  to  lower  BNP  or  NT-proBNP  concen-
rations in  patients  with  LVSD,  it  is  important  to  recognize
hat while  diuretics  are  particularly  potent  in  lower-
ng both  natriuretic  peptides  in  the  context  of  marked
levations of  these  biomarkers  (i.e.  BNP  ≥  500  pg/mL;
T-proBNP ≥  5000  pg/mL),  titration  of  other  agents  such
s vasodilators,  beta-blockers  or  aldosterone  antagonists
ould be  indicated  ﬁrst,  as  would  continuous  reassess-
ent of  salt  and  water  restriction,  medication  adherence,
mprovement of  heart  rhythm  control  for  those  with  atrial
Natriuretic  and  chronic  heart  failure  management  
Figure 5. Up-titration of heart failure (HF) medications in the
STARS-BNP trial. As has been seen in each biomarker-guided heart
failure  trial, BNP-guided care in this study led to signiﬁcant upward
adjustment  of HF medications, a strategy that was well tolerated.
ACE:  angiotensin-converting enzyme; BNP: B-type natriuretic pep-
tide;  NS: not signiﬁcant.
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Table  5  Recommendations  for  optimal  application  of  biomark
Clinicians  should  be  familiar  with  the  complex  physiology  that  
HF
BNP and  NT-proBNP  concentrations  should  be  regarded  as  the  b
Caregivers should  serially  measure  BNP  or  NT-proBNP  concentra
measurements provide  superior  prognostic  information  to  sin
When  using  BNP  or  NT-proBNP,  good  knowledge  of  the  target  co
(BNP  ∼125  pg/mL;  NT-proBNP  1000  pg/mL);  the  closer  to  the
Clinicians  should  be  aware  that  a  rise  or  fall  of  25%  (NT-proBNP
reﬂecting signiﬁcant  change  in  one  or  more  of  the  factors  de
Clinicians  should  be  knowledgeable  about  the  wide  range  of  th
or  NT-proBNP  concentrations
In order  to  be  successful  in  biomarker-guided  care,  a low  targe
(1000  pg/mL)  is  necessary
Clinicians  should  respect  the  importance  of  natriuretic  peptide
such  thing  as  a  ‘‘reassuring’’  BNP  or  NT-proBNP  concentratio
the patient  may  appear
It may  take  time  and  effort  to  suppress  natriuretic  peptide  con
therapy titrations  may  be  needed  to  achieve  the  goal
Unless  in  cases  of  signiﬁcant  congestion  or  marked  elevation  of
peptide concentrations  should  focus  on  therapies  with  morta
ARBs, beta-blockers,  aldosterone  antagonists,  exercise  thera
resynchronization  therapy
Not all  patients  show  ‘‘response’’  to  BNP-  or  NT-proBNP-guided
medication  is  advised,  with  review  of  salt/water  restriction,
When a  patient  is  truly  optimized  but  is  a  BNP  or  NT-proBNP  ‘‘n
peptide value,  their  prognosis  is  poor  and  alternative  modes
ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocke
amino-terminal pro-B-type natriuretic peptide.47
brillation,  consideration  for  exercise  prescription  and  opti-
ization of  cardiac  resynchronization  therapy.  Indeed,  while
oop  diuretics  may  be  useful  for  controlling  very  high
oncentrations of  BNP  or  NT-proBNP,  high  doses  of  these
gents are  potentially  deleterious  and  biomarker-guided
are should  not  be  used  as  a  ‘‘diuretic  only’’  approach  for
are. Indeed,  studies  have  not  only  suggested  that  it  is  pos-
ible to  improve  care  of  patients  using  BNP  or  NT-proBNP
hrough up-titration  of  agents  other  than  loop  diuretics
Fig. 5),  but  in  one  study,  NT-proBNP-guided  care  allowed  for
he downward  titration  of  loop  diuretics  [40]  —– a  desirable
utcome. Thus,  biomarker-guided  management  appears  to
esult in  an  improvement  in  both  the  assiduousness  of  care
nd the  choice  of  agents  used.  Given  that  an  elevated
NP or  NT-proBNP  concentration  identiﬁes  those  at  high-
st risk  for  adverse  outcome,  it  allows  for  closure  of  the
ell-recognized gap  that  exists  in  such  highest-risk  patients.
Importantly,  across  all  studies,  BNP-  or  NT-proBNP-guided
herapy did  not  lead  to  excessive  risk  of  treatment-related
omplications  consequent  to  mindless  up-titration  of  the-
apies with  subsequent  therapy-related  adverse  outcomes;
his reassures  that  clinicians  did  not  just  use  the  biomarker
easurement while  ignoring  the  rest  of  the  information
ained at  the  bedside,  such  as  symptoms  and  vital  signs.
er-guided  heart  failure  care.
inﬂuences  BNP  or  NT-proBNP  concentrations  in  chronic
iochemical  ‘‘gold  standard’’  for  prognostication
tions  in  chronic  HF  patients,  as  routine  repeated
gle  measurements
ncentration  for  each  is  recommended
 target,  the  lower  the  risk
)  to  40%  (BNP)  is  a biologically  meaningful  change,
termining  release  of  these  peptides
erapeutic  interventions  with  favourable  effects  on  BNP
t  concentration  for  BNP  (∼125  pg/mL)  or  NT-proBNP
 concentrations  in  patients  with  chronic  HF;  there  is  no
n  that  is  above  the  target  value,  no  matter  how  stable
centrations;  more  frequent  ofﬁce  visits  and  drug
 BNP  or  NT-proBNP,  strategies  for  lowering  natriuretic
lity  beneﬁt  in  chronic  HF  care,  such  as  ACE  inhibitors,
py  or  optimization  (or  placement)  of  cardiac
 care;  in  this  setting,  continued  optimization  of
 diet,  lifestyle  and  medication  adherence
on-responder’’  with  an  elevated  ‘‘dry’’  natriuretic
 of  therapy  should  be  considered
r; BNP: B-type natriuretic peptide; HF: heart failure; NT-proBNP:
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hus,  with  conﬁdence,  it  is  fair  to  say  biomarker-guided
herapy does  not  replace  clinical  judgment  —– it  supplements
t.
ot all patients respond equally to
iomarker-guided  care
his  says  less  about  biomarker-guided  HF  care  and  more
bout the  varied  responses  that  patients  show  to  therapeutic
ntervention in  HF.  For  example,  based  on  experience  gained
rom two  of  the  larger  studies  of  this  approach  [43,45],  a
ommonly held  belief  is  that  older  patients  beneﬁt  less  than
ounger patients.  In  point  of  fact,  this  observation  is  likely  to
ave less  to  do  with  the  inadequacies  of  guided  therapy  and
ore to  do  with  the  effects  of  age  on  HF  care.  Compared
ith the  younger  HF  patient,  the  elderly  patient  typically
equires a  different  management  approach,  with  more  grad-
al and  careful  drug  titration.  Intolerances  to  therapies  are
reater in  older  patients  and  goal  drug  doses  are  less  likely
o be  achieved  as  a  consequence.
The  results  of  successful  versus  unsuccessful  trials  follow.
lthough not  universal,  the  unsuccessful  guided  HF  therapy
rials more  often  enrolled  patients  that  were  generally  older.
his is  not  to  say  that  elderly  patients  cannot  respond  to
iomarker-guided care;  indeed,  recent  data  from  the  PRO-
ECT study  imply  that  older  patients  not  only  responded
o NT-proBNP-guided  care  but  had  the  greatest  event  rate
eduction related  to  guided  therapy  and  drove  the  pri-
ary endpoint  of  the  study.  Presumably,  the  answer  lies
n how  care  is  optimized  in  older  subjects  treated  with
uided therapy:  more  gradual  care  and  careful  up-titration
ay be  needed  in  such  patients.  For  example,  in  PROTECT,
lder patients  were  seen  considerably  more  frequently  than
ounger patients  to  achieve  the  intended  biomarker  reduc-
ion.
Another important  consideration  is  the  effect  of  guided
herapy on  outcomes  from  HF  due  to  LVSD  versus  from  HFpEF.
iven the  lack  of  a  clearly  effective  treatment  strategy  of
are for  those  with  HFpEF,  it  is  reasonable  to  expect  that
uided therapy  may  be  more  effective  in  patients  with  LVSD.
his is  not  to  say  that  certain  patients  with  HFpEF  may  not
eneﬁt from  monitoring  using  BNP  or  NT-proBNP  —– the  value
f biomarker-guided  care  in  HFpEF  remains  debated  —– but
he  fact  remains  that  the  therapeutic  approach  for  HFpEF  is
nproven and  clearly  differs  from  that  for  HF  due  to  LVSD.
Resistance  to  natriuretic  peptide  lowering  in  certain
ituations is  not  without  signiﬁcance:  whether  in  an  older
atient, one  with  HFpEF  or  in  any  other  scenario.  ‘‘Non-
esponse’’ in  the  course  of  HF  therapy  (whether  guided
y the  natriuretic  peptide  concentration  or  by  standard  HF
are) is  associated  with  a  terrible  prognosis.  As  above,  in  this
etting, review  of  the  choice  of  and  adherence  to  HF  medi-
ations, as  well  as  careful  examination  of  lifestyle  would  be
ndicated.
If truly  optimized,  the  ‘‘dry’’  BNP  or  NT-proBNP  value  is
n important  piece  of  data  to  consider  in  patients  appar-
ntly managed  as  optimally  as  possible;  if  elevated,  despite truly  optimized  management  programme,  strong  con-
ideration of  alternative  therapeutic  strategies  —– including
nvasive haemodynamic  monitors,  mechanical  support,  car-
iac transplantation  or  palliative  care  initiation  —– would  beJ.L.  Januzzi  Jr.
easonable,  given  the  high  likelihood  for  impending  adverse
utcome.
onclusion
n  conclusion,  biomarker-guided  care  using  either  BNP  or  NT-
roBNP now  has  a  sufﬁcient  evidence  base  to  recommend
ts increased  use  in  the  ofﬁce.  The  available  data  imply  that
hen utilized  in  a  manner  consistent  with  successful  clinical
rials, BNP-  or  NT-proBNP-guided  care  allows  for  safe  opti-
ization of  HF  therapies  and  is  associated  with  signiﬁcant
eductions in  adverse  outcomes.  Recommendations  for  opti-
al application  of  biomarker-guided  heart  failure  care  are
ummarized in  Table  5.
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